SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 17, 2003; DOI 10.1182/blood-2002-11-3333. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-11-3333v1 102/3/1070    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Robillard, N. Articles by Bataille, R. Search for Related Content PubMed PubMed Citation Articles by Robillard, N. Articles by Bataille, R. Related Collections Neoplasia Gene Expression Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 August 2003, Vol. 102, No. 3, pp. 1070-1071 NEOPLASIA Brief report CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma Nelly Robillard, Hervé Avet-Loiseau, Richard Garand, Philippe Moreau, Danielle Pineau, Marie-Josée Rapp, Jean-Luc Harousseau, and Régis Bataille From the Laboratory of Hematology and Institut National de la Santé et de la Recherche Médicale (INSERM) U463, Institute of Biology, Nantes, France; and Department of Clinical Hematology, Nantes, Cedex 01, France CD20 has been reinvestigated in 66 patients with multiple myeloma (MM). Twelve of the patients (18%) expressed CD20, including 5 of 50 patients at diagnosis presenting 100% CD20+ cells. Seven (58%) of 12 CD20+ patients with MM had a small mature plasma cell morphology as opposed to 4 (7%) of 54 with CD20- MM (P = .0001). Of note, 10 (83%) of 12 patients with CD20+ MM had t(11;14) as opposed to 5 of 54 (9%) CD20- patients (P < .001). All the patients with 100% CD20+ cells presented with t(11;14) and 4 of 5 with a small mature plasma cell morphology. Thus, 66% of the patients with t(11;14) expressed CD20, whereas only 4% of the 51 patients lacking such translocation expressed CD20 (P < .0001). In conclusion, CD20 expression is associated with small mature plasma cell morphology and with t(11;14) in patients with MM. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF] A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Haematologica, March 1, 2008; 93(3): 431 - 438. [Abstract] [Full Text] [PDF] F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al. The molecular classification of multiple myeloma Blood, September 15, 2006; 108(6): 2020 - 2028. [Abstract] [Full Text] [PDF] J. R. Cook, M. Hartke, J. Pettay, and R. R. Tubbs Fluorescence in Situ Hybridization Analysis of Immunoglobulin Heavy Chain Translocations in Plasma Cell Myeloma Using Intact Paraffin Sections and Simultaneous CD138 Immunofluorescence J. Mol. Diagn., September 1, 2006; 8(4): 459 - 465. [Abstract] [Full Text] [PDF] S. Ely, M. Di Liberto, R. Niesvizky, L. B. Baughn, H. J. Cho, E. N. Hatada, D. M. Knowles, J. Lane, and S. Chen-Kiang Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma Cancer Res., December 15, 2005; 65(24): 11345 - 11353. [Abstract] [Full Text] [PDF] M. A. Gertz, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, M. R. Litzow, K. J. Henderson, S. A. Van Wier, G. J. Ahmann, and R. Fonseca Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Blood, October 15, 2005; 106(8): 2837 - 2840. [Abstract] [Full Text] [PDF] A. K. Stewart and R. Fonseca Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling J. Clin. Oncol., September 10, 2005; 23(26): 6339 - 6344. [Abstract] [Full Text] [PDF] N. Robillard, C. Pellat-Deceunynck, and R. Bataille Phenotypic characterization of the human myeloma cell growth fraction Blood, June 15, 2005; 105(12): 4845 - 4848. [Abstract] [Full Text] [PDF] G. Mateo, M. Castellanos, A. Rasillo, N. C. Gutierrez, Ma. A. Montalban, Ma. L. Martin, J. Ma. Hernandez, Ma. C. Lopez-Berges, L. Montejano, J. Blade, et al. Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma Clin. Cancer Res., May 15, 2005; 11(10): 3661 - 3667. [Abstract] [Full Text] [PDF] S. H. Lim, Y. Zhang, Z. Wang, R. Varadarajan, P. Periman, and W. V. Esler Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency Blood, March 1, 2004; 103(5): 1971 - 1972. [Full Text] [PDF] R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al. Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report Cancer Res., February 15, 2004; 64(4): 1546 - 1558. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020